A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.

Trial Details

NCT ID
NCT06461156
Phase
PHASE1
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HS-10504
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Males or females, aged ≥ 18 years.
  • Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC
  • Progressive disease on or after prior treatment with EGFR-TKIs.
  • Enrollment will be restricted to participants with evidence of EGFR-positive in tumor as determined by local or central testing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →